Electrocardiography

United States Cardiovascular Devices Market, Size, Share, Forecast 2024-2030 Featuring Abbott Laboratories, Boston Scientific, Edwards Lifesciences, Cardinal Health, Medtronic, GE, J&J, & Siemens - ResearchAndMarkets.com

Retrieved on: 
Monday, April 8, 2024
Health, Medical Devices, Cardiology, Hospital, Cardiac catheterization, Disease, American Heart Association, Stent, Cardiovascular disease, Coronary artery disease, Prevalence, Biotechnology, CVD, ECG, Incidence, Diabetes, Electrocardiography, Public, Research, Mortality, Insight, Death, Risk, Arrhythmia, Diagnosis, Heart failure, CAD, Medical device

Consequently, producers are investing in innovation and developing new cardiovascular devices to satisfy growing healthcare wishes, expanding the increase in the United States cardiovascular devices market.

Key Points: 
  • Consequently, producers are investing in innovation and developing new cardiovascular devices to satisfy growing healthcare wishes, expanding the increase in the United States cardiovascular devices market.
  • Technology is pivotal in employing growth in the United States cardiovascular devices market.
  • Numerous market players actively enforce strategic tasks, propelling an increase in the United States cardiovascular devices market.
  • In the United States cardiovascular devices market, diagnostics and monitoring devices have a significant presence
    The United States cardiovascular device market is broken up by device type into Diagnostics and Monitoring Devices and Therapeutic and Surgical Devices.

HeartSciences Reports Second Quarter Fiscal 2024 Financial Results

Retrieved on: 
Thursday, December 14, 2023
Shift, Science, Global Health, Classification, ECG, FDA, HSCS, Electrocardiography, Patent, American Medical Association, Growth, IPO, Overalls, CPT, Diagnosis, Cardiovascular disease, Intelligence, Algorithm, De novo, Medical device

Southlake, TX, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today reported financial results for the second quarter fiscal 2024 ended October 31, 2023 and provided a business update.

Key Points: 
  • Southlake, TX, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today reported financial results for the second quarter fiscal 2024 ended October 31, 2023 and provided a business update.
  • After the fiscal second quarter's close, we successfully completed a series of actions including an equity raise and debt conversion that remedied the Nasdaq shareholders’ equity deficiency.
  • After the close of the second fiscal quarter 2024, the Company raised $9.3 million in net proceeds from sales of common stock and converted $1.1 million of debt to equity.
  • Further, HeartSciences closed a series of license agreements with Mount Sinai which results in Mount Sinai becoming a material shareholder in the Company.

Catapult Launches Advanced Integrated Heart Rate Solution for their Vector Athlete Monitoring System

Retrieved on: 
Friday, November 10, 2023
ECG, Vector, Movement, Athlete, Health, Catapult, Electrocardiography, Silicon, Heart rate, Medical imaging, Boston

The Elite Vest 2.3, combined with an advanced heart rate algorithm, delivers best-in-class heart rate data accuracy and reliability, without the need for a secondary heart rate device.

Key Points: 
  • The Elite Vest 2.3, combined with an advanced heart rate algorithm, delivers best-in-class heart rate data accuracy and reliability, without the need for a secondary heart rate device.
  • In addition to the design enhancements of the vest, Catapult has developed an advanced heart rate algorithm which smooths data spikes and delivers precise and consistent heart rate data during high intensity movements.
  • The Elite Vest 2.3 and new heart rate algorithm have been tested extensively with elite customers, and the heart rate data accuracy has been validated against other major heart rate data providers.
  • The new heart rate algorithm is compatible with all Vector devices, and is available to all Catapult Vector customers now to provide enhanced heart rate data accuracy.

HeartSciences Named Electrocardiography Advancement Specialists of the Year 2023 - USA in the Global Health & Pharma Excellence Awards

Retrieved on: 
Monday, September 11, 2023
HSCS, GHP, Intelligence, Global Health, Electrocardiography, Artificial intelligence, AI, Medical device

Southlake, TX, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-based medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that it has been named Electrocardiography Advancement Specialists of the Year 2023 – USA, in the Global Health & Pharma (GHP) Global Excellence Awards.

Key Points: 
  • Southlake, TX, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-based medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that it has been named Electrocardiography Advancement Specialists of the Year 2023 – USA, in the Global Health & Pharma (GHP) Global Excellence Awards.
  • "We are honored to receive this award and be recognized for advancing the field of electrocardiography using AI," said Andrew Simpson, CEO of HeartSciences.
  • HeartSciences was selected as a winner in recognition of its innovative work in AI-enabled electrocardiography advancement with its MyoVista® wavECG™ Technology.
  • The GHP Excellence Awards are presented annually to companies that have demonstrated excellence in their respective industries.

Global Neonatal Monitoring Technology Innovation Analysis Report 2023: From NICUs to Homes - How Noninvasive Neonatal Monitoring Devices Drive Early Detection and Safe Transitions

Retrieved on: 
Saturday, July 22, 2023
Parent, Infant, Electrocardiography, ECG, Health, Vital signs, Patent, Life, Environment, PEST, Nicu's Spoon Theater Company, Nursing, Medical imaging, Dietary supplement

It focuses on key noninvasive devices, including wearable and contactless devices in high demand for neonatal monitoring.

Key Points: 
  • It focuses on key noninvasive devices, including wearable and contactless devices in high demand for neonatal monitoring.
  • The study also provides clinical trial analysis of neonatal monitoring devices; political, economic, social, and technological (PEST) analysis; customer journey mapping; future technology outlook; and patent landscape.
  • Neonatal monitoring medical technologies monitor newborn babies' health and vital signs in the first few days or weeks of their life.
  • Some commonly used neonatal monitoring devices include electrocardiography (ECG) monitors, pulse oximetry monitors, temperature monitors, and respiratory monitors.

Masimo Announces FDA 510(k) Clearance of Radius VSM™

Retrieved on: 
Monday, June 5, 2023
Public Relations, Investor Relations, General Health, Health, FDA, Medical Devices, Communications, Hospitals, Health Technology, Blood pressure, Cleveland Clinic, Pulse, Freedom, Anesthesiology, Respiratory rate, AVL, University Hospitals Cleveland Medical Center, Radius, Health technology, ECG, Multimedia, Temperature, Orientation, Doctor of Philosophy, Movement, II, FGS, Acoustic, Cardiac electrophysiology, Hospital, MASI, Oxygen saturation (medicine), MD, Patient, Nursing, Risk, Protocol, Electrocardiography, Perioperative medicine, Heart rate, Peter Hancock (professor), III, Halo, Telemetry, Safety, Medical device, Medical imaging, AVR

Masimo (NASDAQ: MASI) today announced that Radius VSM™ , a patient-worn, continuous multi-parameter vital signs monitor, has received FDA 510(k) clearance.

Key Points: 
  • Masimo (NASDAQ: MASI) today announced that Radius VSM™ , a patient-worn, continuous multi-parameter vital signs monitor, has received FDA 510(k) clearance.
  • Designed on a modular platform, Radius VSM allows clinicians to monitor a wide variety of physiological measurements, including Masimo SET® pulse oximetry , noninvasive blood pressure, temperature, respiration rate, and electrocardiography (ECG).
  • By combining the reliability and accuracy of larger bedside monitors with the comfort and freedom of a wearable device, Radius VSM allows ambulation and movement while ensuring patients remain continuously monitored.
  • From a technical perspective, we had no doubt about the reliability of the solution as we have been working with Masimo for many years now.

Lucintel Expects the Global Sensor Market to Reach $295 Billion by 2027

Retrieved on: 
Friday, April 21, 2023
Analog Devices, NXP Semiconductors, Research report, Health, Electronics, Internet, Internet of things, Health care, Infineon Technologies, ECG, Radar, TPMS, Miniaturization, ABB, Texas Instruments, STMicroelectronics, Growth, Sony, Automation, Consumer electronics, Instrumentation, Oil, Electrocardiography, ADAS

The global sensor market is expected to reach an estimated $295 billion by 2027 with a CAGR of 11.5% from 2021 to 2027.

Key Points: 
  • The global sensor market is expected to reach an estimated $295 billion by 2027 with a CAGR of 11.5% from 2021 to 2027.
  • Lucintel, a leading global strategic consulting and market research firm, has analyzed growth opportunities in the global sensor market by product type, end use industry, and region.
  • Lucintel has prepared a comprehensive research report entitled " Sensor Market Report: Trends, Forecast and Competitive Analysis "
    For any questions related to sensor market or related to TPMS sensor, 02 sensor, mass air flow sensor, oxygen sensor, mass flow light sensor, knock sensor, tire pressure sensor, motion sensor, proximity sensor, sensor companies, sensor market size, sensor market share, sensor analysis, write Lucintel analyst at email: [email protected] .
  • If you wish to deep dive on some other segments of sensor or related market then look into below relevant reports from Lucintel.

Atea Announces Presentation of Bemnifosbuvir Data Demonstrating Reduced Hospitalizations for COVID-19 Patients at 2023 European Congress of Clinical Microbiology & Infectious Diseases

Retrieved on: 
Wednesday, April 12, 2023
Bemnifosbuvir, Truncation, Therapy, Hospital, Virology, Dengue virus, COVID-19, Atea, Pharmacokinetics, Viral, ICAR, QRS, Doctor of Philosophy, QT, QT interval, Plasma, Congress, ECCMID, International Conference on Population and Development, Antiviral Research, Patient, European, Risk, Political moderate, Adolescence, Electrocardiography, Heart rate, Conference, HCV, Infection, Safety, Pharmaceutical industry

These results are being presented at the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), which is taking place April 15-18, 2023 in Copenhagen, Denmark.

Key Points: 
  • These results are being presented at the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), which is taking place April 15-18, 2023 in Copenhagen, Denmark.
  • “The MORNINGSKY data also highlight additional potential clinical benefits of bemnifosbuvir.
  • Adverse events leading to treatment discontinuation were observed in 2.8% of patients treated with bemnifosbuvir compared to 7% of patients receiving placebo.
  • Atea will also present clinical data for AT-752, an oral double prodrug of a guanosine nucleotide analog for the treatment of dengue virus, at ECCMID 2023.

Veterinary Dentistry Specialists in Mt. Laurel, NJ, Adds a Veterinary Cardiologist to Team of Board-Certified Specialists in Dentistry and Anesthesia

Retrieved on: 
Monday, April 10, 2023
Health, Consumer, Surgery, Other Health, Dental, Pets, Veterinary, Blood pressure, Holter, University, Heart, VDS, Dog, Professional, Echocardiography, Veterinary dentistry, Blue Pearl, VMD, Exercise intolerance, Cough, Anesthesia, Journal of Veterinary Internal Medicine, University of Pennsylvania School of Veterinary Medicine, Patient, Risk, Cardiology, Pericardial effusion, Heart murmur, Abdomen, Electrocardiography, Diplomate of National Board, Heart rate, American College, Veterinary medicine, DVM, Anesthesiology, Cat, Dentistry, Medical imaging

Laurel, NJ, office of Veterinary Dentistry Specialists (VDS), a veterinary dentistry and oral surgery practice, has added board-certified veterinary cardiologist Megan King, VMD, DACVIM (Cardiology), to its roster of dental and anesthesia specialists.

Key Points: 
  • Laurel, NJ, office of Veterinary Dentistry Specialists (VDS), a veterinary dentistry and oral surgery practice, has added board-certified veterinary cardiologist Megan King, VMD, DACVIM (Cardiology), to its roster of dental and anesthesia specialists.
  • Adding comprehensive outpatient veterinary cardiology services makes VDS the first and only veterinary dentistry and oral surgery practice in the nation with anesthesiology and cardiology specialists available to care for each patient.
  • Cardiology services are also available for pet patients who do not need dentistry services.
  • She then earned Diplomate status by becoming board certified in veterinary cardiology by the American College of Veterinary Internal Medicine.

Wearable ECG Devices Global Market Report 2022: Sector to Reach $35.45 Billion by 2027 at a 19.3% CAGR

Retrieved on: 
Friday, January 20, 2023
EKG, Heart, Electrocardiography, Software, Diagnosis, Apple Watch, Electronics, Hospital, Reading, Alivecor, FDA, Growth, Arrhythmia, AI, Samsung Galaxy Watch 3, Holter, Artificial intelligence, Atrial fibrillation, AF, Clothing, ML, Acquisition, ECG, Fitbit, DL, Communication, Medical imaging, Medical device

DUBLIN, Jan. 20, 2023 /PRNewswire/ -- The "Wearable ECG Devices Market - Global Outlook & Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Jan. 20, 2023 /PRNewswire/ -- The "Wearable ECG Devices Market - Global Outlook & Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.
  • The emergence of advanced sensors, AI, ML, and DL in wearable ECG is boosting the wearable ECG devices market.
  • Such integration of ECG with smartwatches contributes to the growth of the wearable ECG devices market.
  • Owing to the benefits of ambulatory monitoring, wearable ECG devices market players are significantly focusing on developing user-friendly, safe & accurate ambulatory ECG devices.